Intec Pharma (NTEC)

Business description

Intec Pharma is a drug delivery company that has developed the accordion pill, a novel gastroretentive controlled release formulation. The company is currently using this technology to develop AP-CDLD for Parkinson’s in Phase III and AP-ZP for insomnia in Phase II.

Stock data

Market cap.NIS260.5m
Last closeNIS18.96
High / Low (52 weeks)NIS23.4 / NIS15.4
Stock market listingTel Aviv Stock Exchange
Forecast net cash (US$m)16.4
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual(0.3)4.910.6
Relative *(0.7)2.25.4

* % Relative to local index

Other companies in sector Show

4SC aap Implantate
Aastrom Biosciences AB Science
Abcam Abivax SA
Ablynx Abzena
Acarix Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Acucela
Addex Therapeutics Adherium
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris AFT Pharmaceuticals
Agennix Akari Therapeutics
Alchemia Alexza Pharmaceuticals
Algeta Alimera Sciences
ALK Abello Alkermes
Allergy Therapeutics Alliance Pharma
Allium Medical Solutions Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Angle Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Aratana Therapeutics Ardea Biosciences
Ardelyx Arena Pharmaceuticals
arGEN-X Argos Therapeutics
Ariad Pharmaceuticals Arix Bioscience
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Ascendis Pharma Astex Pharmaceuticals
Athersys Atossa Genetics
Avacta Group Avalanche Biotechnologies
AVEO Pharmaceuticals Avita Medical
Balda Basilea Pharmaceutica
Bavarian Nordic Bellus Health
Benitec Biopharma BioCryst Pharmaceuticals
BioInvent BioLight Life Sciences
BioLineRx Biondvax Pharmaceuticals
Bionomics Bionor Pharma
Biota Holdings Biotie Therapies Corp
Biotron Bluebird Bio
Bone Therapeutics BrainStorm Cell Therapeutics
BTG C4X Discovery Holdings
Can-Fite BioPharma Capstone Therapeutics
Carmat Cell Therapy
Celldex Therapeutics Cellectis
Cellular Biomedicine Group Celyad
Cerulean Pharma Circadian Technologies
Clal Biotechnology Clavis Pharma
Cleveland BioLabs Clinigen Group
Clinuvel co.don AG
Collplant Holdings Consort Medical
Corium International Crescendo
Crossject Curis
Cytori Therapeutics Cytos Biotechnology
CytRx Corporation DBV Technologies
Dechra Pharmaceuticals Delcath Systems
Deltex Medical Derma Sciences
DiaSorin Diaxonhit
e-Therapeutics Egalet Corporation
EKF Diagnostics Emergent BioSolutions
Endocyte Epigenomics
Erytech Pharma Esperion Therapeutics
Evotec Exact Sciences
Exelixis Factor Therapeutics
Formycon Forward Pharma
Fresenius SE & Co. KGaA Futura Medical
Galapagos Galmed Pharmaceuticals
Genedrive Genfit
Genkyotex Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
GW Pharmaceuticals Halozyme Therapeutics
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunicum Immunodiagnostic Systems Holdings
Immunovia ImmuPharma
Imprimis Pharmaceuticals Imugene
Incyte Corporation Infinity Pharmaceuticals
Innate Pharma Insmed
International Stem Cell Invion
Ion Beam Applications Ipsogen
Iridex Ironwood Pharmaceuticals
Islet Sciences Ixico
KaloBios Pharmaceuticals Karolinska Development
Keryx Biopharmaceuticals Kiadis Pharma
LCA-Vision LeMaitre Vascular
Lifeline Scientific LifeWatch
Ligand Pharmaceuticals Lipocine
Lombard Medical Technologies MagForce
Mast Therapeutics Medcom Tech
Medicago MediciNova
Medigene Medivir
Merrimack Pharmaceuticals Merrion Pharmaceuticals
Mesoblast MethylGene
Midatech Pharma MISSION Therapeutics
Molecular Partners MolMed
Mologen Momenta Pharmaceuticals
MorphoSys Nanobiotix
Nanosonics Navidea Biopharmaceuticals
Nektar Therapeutics NeoStem
Neovacs NetScientific
NeuroVive Pharmaceutical Newron Pharmaceuticals
Nexstim NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novacyt Novogen
NPS Pharmaceuticals Nuevolution
Ocata Therapeutics Omega Diagnostics Group
Omeros Corporation OncoGenex Pharmaceuticals
Oncolytics Biotech Inc OncoMed Pharmaceuticals
Onconova Therapeutics Oncothyreon
Onxeo Onyx Pharmaceuticals
Opexa Therapeutics OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Oryzon Genomics
Ossur OvaScience
Oxford BioMedica Pacific Edge
Paion Paladin Labs
Patheon PDL BioPharma
Pharmacyclics PharmaMar
Pharmaxis Pharming Group
Photocure Phylogica
Pixium Vision Pluristem Therapeutics
Prescient Therapeutics Prima BioMed
Probiodrug ProMetic Life Sciences
Prosensa Proteome Sciences
PsiOxus QRxPharma
Quantum Genomics Quantum Pharmaceuticals
RedHill Biopharma Regeneus
Relmada Therapeutics ReNeuron Group
Resverlogix REVA Medical
Rovi ROVI Laboratorios Farmaceuticos
RXi Pharmaceuticals Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Shire Sierra Oncology
Silence Therapeutics Simavita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
SymBio Pharmaceuticals Synairgen
Synergy Health Synta Pharmaceuticals
TearLab Corp Tekmira
TESARO Theraclion
Therapix Bioscience Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Tissue Therapies
Titan Pharmaceuticals Tonix Pharmaceuticals
Topotarget Touchstone Innovations
Transgene Trillium Therapeutics
Trimel Pharmaceuticals TruScreen Ltd
TxCell UCB
UDG Healthcare uniQure NV
Universal Biosensors VBI Vaccines
Vectura Verastem
Verisante Technology Vernalis
Verona Pharma Vertex Pharmaceuticals
Viralytics ViroPharma
Vivalis Vivus
VolitionRx WaferGen Biosystems
Wilex Xbrane Biopharma
Xencor Zafgen
Zealand Pharma Ziopharm Oncology

Company news

Intec Pharma Announces CEO Change

Wed, 03 May 2017 08:05:21 GMT

BRIEF-Intec Pharma Ltd files for mixed shelf of up to $100.0 mln

Tue, 06 Jun 2017 21:33:45 GMT

Intec Pharma Granted Chinese Patent for Accordion Pill

Mon, 31 Oct 2016 12:00:00 GMT

EPS for Intec Pharma Ltd (NTEC) Expected At $-0.31

Wed, 21 Jun 2017 13:31:39 GMT

Intec Pharma raises $27m in Nasdaq IPO

Tue, 04 Aug 2015 11:35:47 GMT

Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2015A 0.0 (8.3) (7.2) (92.16) N/A N/A
2016A 0.0 (14.5) (13.4) (116.72) N/A N/A
2017E 0.0 (13.8) (12.8) (88.60) N/A N/A
2018E 0.0 (14.6) (13.6) (89.34) N/A N/A

Last updated on 22/05/2017

Investment summary

Intec Pharma is a drug delivery company that has developed a novel drug delivery device termed the accordion pill (AP), a folded, multilayer membrane packaged into a normal capsule, which expands to a sheet within the stomach to many times its original size. This property causes the pill to be retained in the stomach for up to 12 hours. This is ideal for drugs with local activity in the stomach or upper digestive tract or with poor solubility. AP-CDLD, a controlled release formulation of carbidopa and levodopa for Parkinson’s is in Phase III with enrollment expected to complete by the end of the year with data in mid-2018. They have also initiated a Phase I trial of AP-CBD/THC, their cannabinoid program.

Last updated on 01/06/2017

Industry outlook

Parkinson’s disease is a neurodegenerative disease in which the dopamine secreting neurons in the brain are lost, leading to severe motor defects and cognitive impairment. Approximately one million people in the US have Parkinson’s.

Last updated on 01/06/2017

Key management

John W Kozarich, Chairman
Zeev Weiss, CEO
Nir Sassi, CFO

Company address

12 Hartom st. (RMPE building)
P.O.Box 45219
Jerusalem
91450
Israel
+972-2-5864657
View website